Neha Patil (Editor)

Ruboxistaurin

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
ATC code
  
none

PubChem CID
  
153999

ChemSpider
  
135727

Molar mass
  
468.546 g/mol

CAS Number
  
169939-94-0

IUPHAR/BPS
  
5263

UNII
  
721809WQCP

Ruboxistaurin httpsuploadwikimediaorgwikipediacommonsthu

Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.

On February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the US FDA for ruboxistaurin, with a request for an additional clinical trial, which would take 5 years to complete.

Mechanism of action

Ruboxistaurin is an inhibitor of protein kinase C-beta.

References

Ruboxistaurin Wikipedia